You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Autophagic Programmed Cell Death

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC (NSCLC) Trial in Shanghai (Tumor treating fields(EFE-P100), Docetaxel injection)

Not yet recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • Tumor treating fields（EFE-P100）
  • Docetaxel injection
  • Shanghai, China
    Shanghai Pulmonary Hospital
Dec 21, 2022

NSCLC Trial in Wuhan (Cadonilimab, Pemetrexed, Carboplatin)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Wuhan, Hubei, China
    Qian Chu
Aug 18, 2023

NSCLC, Solid Tumors, Programmed Cell Death-1 (PD1, PD-1) Trial (MK-2870, Pembrolizumab, Carboplatin)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • +4 more
  • MK-2870
  • +2 more
  • (no location specified)
Sep 15, 2023

Acute Lymphoblastic Leukemia in Pediatric Trial in Sohag (flow cytometric immunophynotyping)

Not yet recruiting
  • Acute Lymphoblastic Leukemia in Pediatric
  • flow cytometric immunophynotyping
  • Sohag, Egypt
    Sohag University Hospital
Jun 19, 2022

Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell

Recruiting
  • Primary Immune Deficiency
    • Bethesda, Maryland
    • +6 more
    Feb 2, 2023

    PD1/PDL1 Inhibitors Treatment Duration in Patients With NSCLC

    Recruiting
    • Non-small Cell Lung Cancer
    • Monza, Italy
      ASST-Monza Ospedale San Gerardo
    Jun 9, 2022

    Esophageal Squamous Cell Carcinoma Trial (Paclitaxel, Irinotecan, Pembrolizumab)

    Recruiting
    • Esophageal Squamous Cell Carcinoma
    • Chuo-ku, Tokyo, Japan
      National Cancer Center Hospital ( Site 3700)
    Jan 31, 2023

    Non Small Cell Lung Cancer, Immune Checkpoint Inhibitor, EGFR Exon 21 Mutation Trial in Peking (Pembrolizumab, pemetrexed,

    Not yet recruiting
    • Non Small Cell Lung Cancer
    • +2 more
    • Peking, China
      Peking Union Medical College Hospital
    Nov 16, 2023

    Tumor-Infiltrating Lymphocytes and Programmed Cell Death -

    Recruiting
    • Breast Cancer
    • +2 more
    • Observational Study
    • Lucknow, Uttar Pradesh, India
      Sanjay Gandhi Postgraduate Institute of Medical Sciences
    Feb 11, 2022

    Hepatocellular Carcinoma Non-resectable, Transarterial Chemoembolization, Tyrosine Kinase Inhibitor Trial in Chengdu (lenvatinib

    Enrolling by invitation
    • Hepatocellular Carcinoma Non-resectable
    • +3 more
    • lenvatinib + sindilimab/carrelizumab
    • TACE
    • Chengdu, Sichuan, China
      West China Hospital of Sichuan University
    May 23, 2022

    Metastatic Nonsmall Cell Lung Cancer, Non Small Cell Lung Cancer Trial in Philadelphia (Stereotactic Body Radiotherapy)

    Active, not recruiting
    • Metastatic Nonsmall Cell Lung Cancer
    • Non Small Cell Lung Cancer
    • Stereotactic Body Radiotherapy
    • Philadelphia, Pennsylvania
      Philadelphia CyberKnife
    Mar 15, 2022

    Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor, Radiotherapy Trial in Guangzhou (Toripalimab,

    Not yet recruiting
    • Muscle-Invasive Bladder Carcinoma
    • +2 more
    • Guangzhou, Guangdong, China
      Cancer Center, Sun Yat-sen University
    Aug 3, 2023

    Locally Advanced Cervical Cancer Trial in Villejuif (Atezolizumab, Radiotherapy, Cisplatin)

    Recruiting
    • Locally Advanced Cervical Cancer
    • Villejuif, Val De Marne, France
      Gustave Roussy
    Feb 15, 2022

    Anti-Programmed Cell Death Protein 1 Immunotherapy in Head and

    Recruiting
    • Head and Neck Cancer
    • Strasbourg, France
      Institut de cancérologie Strasbourg Europe
    Apr 14, 2022

    Malignant Melanoma Trial (tremelimumab/durvalumab, ipilimumab/nivolumab and nivolumab monotherapy)

    Withdrawn
    • Malignant Melanoma
    • tremelimumab/durvalumab, ipilimumab/nivolumab and nivolumab monotherapy
    • (no location specified)
    Nov 12, 2021

    Recurrent/Metastatic Gastric Cancer Trial in Seoul (Nivolumab, Paclitaxel)

    Completed
    • Recurrent/Metastatic Gastric Cancer
    • Nivolumab, Paclitaxel
    • Seoul, Korea, Republic of
      Yonsei University Health System, Severance Hospital
    Sep 9, 2022

    Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Chapel Hill (Nivolumab, Pembrolizumab)

    Recruiting
    • Relapsed Hodgkin Lymphoma
    • Refractory Hodgkin Lymphoma
    • Nivolumab
    • Pembrolizumab
    • Chapel Hill, North Carolina
      Lineberger Comprehensive Cancer Center at University of North Ca
    Jul 22, 2022

    NSCLC Trial (pembrolizumab, carboplatin, paclitaxel)

    Active, not recruiting
    Has Results
    • Non-small Cell Lung Cancer
    • pembrolizumab
    • +3 more
    • (no location specified)
    Aug 18, 2022

    NSCLC Trial (pembrolizumab, carboplatin, paclitaxel)

    Active, not recruiting
    Has Results
    • Non-small Cell Lung Cancer
    • pembrolizumab
    • +3 more
    • (no location specified)
    Aug 18, 2022

    NSCLC Trial in Marietta, Taichung City, Tainan (Sacituzumab Govitecan, Pembrolizumab)

    Recruiting
    • Carcinoma, Non-Small-Cell Lung
    • Sacituzumab Govitecan
    • Pembrolizumab
    • Marietta, Georgia
    • +2 more
    Jan 27, 2023

    Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma Trial in Changchun (Rituximab,

    Recruiting
    • Peripheral T-Cell Lymphoma, Not Otherwise Specified
    • Angioimmunoblastic T-cell Lymphoma
    • Changchun, Jilin, China
      The First Bethune Hospital of Jilin University
    Apr 7, 2023

    Fruquintinib Plus PD-1 in Refractory MSS Metastatic Colorectal

    Completed
    • Colorectal Cancer
    • Fruquintinib combined with anti-PD-1 antibodies
    • ChangSha, Hunan, China
      Hunan Cancer Hospital
    Aug 27, 2023

    Liver Diseases, Hepatocellular Carcinoma, Immunotherapy Trial in Guangzhou (bTAE-HAIC, Lenvatinib, Sintilimab)

    Not yet recruiting
    • Liver Diseases
    • +4 more
    • bTAE-HAIC
    • +2 more
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    Sep 30, 2023

    Liver Diseases, Hepatocellular Carcinoma, Immunotherapy Trial in Guanzhou (bTAE-HAIC, Lenvatinib, Camrelizumab)

    Not yet recruiting
    • Liver Diseases
    • +4 more
    • bTAE-HAIC
    • +2 more
    • Guanzhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    Sep 24, 2023

    Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite

    Completed
    • Metastatic Colorectal Adenocarcinoma
    • regorafenib plus anti-PD-1 antibodies
    • Changsha, Hunan, China
      Hunan Cancer hospital
    Jul 4, 2023